Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

BACKGROUND: Today, heart failure is one of the leading causes of death and disability in most developed and developing countries. By 2030, more than 23.3 million people are projected to die of cardiovascular diseases each year, and the prevalence of heart failure is expected to increase by 25%. One...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravangard, Ramin, Jalali, Farideh Sadat, Hajahmadi, Marjan, Jafari, Abdosaleh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476319/
https://www.ncbi.nlm.nih.gov/pubmed/37665450
http://dx.doi.org/10.1186/s13561-023-00457-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476319/
https://www.ncbi.nlm.nih.gov/pubmed/37665450
http://dx.doi.org/10.1186/s13561-023-00457-4

Ejemplares similares